gsk curevac - Search News

News

GSK, CureVac to receive $740M

Reuters on MSN · 1d

CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the mRNA vaccine technology that was at the forefront of the world's fight against COVID-19.

PharmExec · 19h

GSK Gains $370 Million Upfront, Reduced Royalties in CureVac mRNA Patent Settlement Agreement with Pfizer, BioNTech

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional payments and global royalty benefits if BioNTech’s acquisition of CureVac closes.

Seeking Alpha on MSN · 1d

GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over mRNA vaccine patents. Read more here.

Pharmalittle: We’re reading about Trump and drug prices, an FDA plan for U.S. manufacturing, and more

The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere to ...

TipRanks on MSN1d

GSK provides update on U.S. settlement CureVac/BioNTech mRNA patent litigation

GSK (GSK) announces that, in connection with the mRNA patent settlement reached between CureVac (CVAC) and BioNTech on 7 August 2025, the Company ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results